Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Bridion (sugammadex) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.
• This summary is based on the review of 26 systematic review(s)/meta-analysis(es). ^[1-26]
• Sugammadex reduced postoperative pulmonary complications (OR 0.67, 95% CI 0.47-0.95) and showed a robust reduction in patients with ARISCAT-defined risk factors (RR 0.66, 95% CI 0.54-0.80).
• Lower rates of prolonged postoperative ileus were observed with sugammadex compared to cholinesterase inhibitors (OR 0.44, 95% CI 0.25-0.77).
• Sugammadex significantly shortened the time to achieve a TOF ratio ≥ 0.9 in both adult and pediatric populations, with no significant difference in reversal time between CBW and TBW dosing in morbidly obese patients.
• Sugammadex was associated with a lower risk of postoperative nausea and vomiting compared to neostigmine (RR 0.85, 95% CI 0.76-0.94).
• Sugammadex is generally well-tolerated, with a lower incidence of adverse events compared to cholinesterase inhibitors. No major complications such as cardiac arrest or refractory bradycardia were reported.
• The incidence of anaphylaxis associated with sugammadex was rare, occurring in 0.02% to 0.04% of cases based on observational studies.
• Pediatric patients experienced a lower incidence of adverse effects with sugammadex (RR 0.44, 95% CI 0.24-0.82) and reduced rates of postoperative nausea and vomiting (OR 0.17, 95% CI 0.07-0.40).
• There is no population types or subgroups information available in the reviewed studies.